Evidence for Andexanet Alpha in Reversing Intracerebral Hemorrhage due to Factor Xa Inhibitors?

Affiliations

¹ Department of Pharmacy Services, University of Maryland Medical Center, Baltimore (M.J.A.).
² Program in Trauma, Department of Neurology, University of Maryland School of Medicine, Baltimore (N.B.).

Editorial

Michael J Armahizer et al. Stroke. 2021 Jun.

. 2021 Jun;52(6):2106-2108.

doi: 10.1161/STROKEAHA.120.031825. Epub 2021 May 10.

¹ Department of Pharmacy Services, University of Maryland Medical Center, Baltimore (M.J.A.).
² Program in Trauma, Department of Neurology, University of Maryland School of Medicine, Baltimore (N.B.).

No abstract available

Keywords: Editorials; anticoagulant; atrial fibrillation; embolism; intracranial hemorrhage.

Comment on

Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy.
Demchuk AM, Yue P, Zotova E, Nakamya J, Xu L, Milling TJ Jr, Ohara T, Goldstein JN, Middeldorp S, Verhamme P, Lopez-Sendon JL, Conley PB, Curnutte JT, Eikelboom JW, Crowther M, Connolly SJ; ANNEXA-4 Investigators. Demchuk AM, et al. Stroke. 2021 Jun;52(6):2096-2105. doi: 10.1161/STROKEAHA.120.030565. Epub 2021 May 10. Stroke. 2021. PMID: 33966491 Free PMC article. Clinical Trial.